
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is facing long-term challenges in their competitive commercial and clinical development landscapes, which could impact the visibility and growth potential of their key drug, Cabometyx. However, they have a strong balance sheet and sustainable profitability compared to their mid-cap peers, making them an attractive investment opportunity for the future if they are able to execute on their pipeline and business development plans. A potential opportunity to invest in Exelixis may arise if a more attractive entry point becomes available.
Bears say
Exelixis is facing several challenges that impact its outlook, including generic erosion of its existing franchises, potential safety and tolerability concerns with its independent solution to Cabometyx, zanzalintinib, and possible long-term dilution risk. Additionally, the company's upcoming PDUFA date for its potential approval for zanzalintinib in 3L MSS mCRC, as well as data disclosures and trial initiations related to the drug, will be important factors for investors to watch. However, the company's expansion of its sales force and efforts to accelerate Cabometyx utilization may provide some support for its stock, though our negative outlook remains largely unchanged.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares